TransThera Sciences (Nanjing) Inc
HKEX:2617
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
H
|
Hagar hf
ICEX:HAGA
|
IS |
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CN |
T
|
TransThera Sciences (Nanjing) Inc
HKEX:2617
|
27.8B HKD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
365.4B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
184.6B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
173.9B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.3B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.7B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
67B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
39.6B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
Other Profitability Ratios
TransThera Sciences (Nanjing) Inc
Glance View
TransThera Sciences (Nanjing) Inc is a CN-based company operating in Biotechnology industry. The company is headquartered in Nanjing, Jiangsu. The company went IPO on 2025-06-23. TransThera Sciences (Nanjing) Inc is a China-based biopharmaceutical company principally focusing on discovering and developing innovative small molecule therapies for oncology, inflammatory and cardiometabolic diseases. The firm's core product Tinengotinib is a registrational clinical stage, internally discovered and developed, MTK inhibitor indicated for certain relapsed or refractory, drug-resistant solid tumors. The firm's oncology pipeline includes TT-00973 (against AXL), TT-01488 (for hematologic malignancies), TT-01688 (for inflammatory diseases) and TT-00920 (for chronic heart failure). The products are capable of being efficacious in a broad range of cancer types (including prostate cancer, HCC, breast cancer, and BTC). The company is also applied to cure hepatocellular carcinoma, breast cancer, biliary tract cancer and Pan-FGFR solid tumor.
